A Phase II Study of Modified Lenalidomide, Bortezomib and Dexamethasone for Transplant-Ineligible Patients With Newly Diagnosed Multiple Myeloma
Phase of Trial: Phase II
Latest Information Update: 02 Nov 2018
At a glance
- Drugs Bortezomib (Primary) ; Dexamethasone (Primary) ; Lenalidomide (Primary)
- Indications Multiple myeloma
- Focus Therapeutic Use
- 12 Mar 2018 Status changed from active, no longer recruiting to completed.
- 12 Dec 2017 Results presented at the 59th Annual Meeting and Exposition of the American Society of Hematology
- 17 Feb 2017 Planned End Date changed from 1 Dec 2016 to 1 Dec 2017.